Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$521M |
| 2 |
Becton Dickinson
BDX
|
+$411M |
| 3 |
GE Aerospace
GE
|
+$361M |
| 4 |
IBM
IBM
|
+$305M |
| 5 |
Philip Morris
PM
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$455M |
| 2 |
NetEase
NTES
|
+$451M |
| 3 |
Medtronic
MDT
|
+$398M |
| 4 |
NVIDIA
NVDA
|
+$348M |
| 5 |
Netflix
NFLX
|
+$332M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Technology | 14.39% |
| 3 | Financials | 10.63% |
| 4 | Industrials | 9.92% |
| 5 | Consumer Discretionary | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APU
2576
DELISTED
AmeriGas Partners, L.P.
APU
| $1.26M | ﹤0.01% |
+27,200
| New | +$1.22M |
|
|
ECYT
2577
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $1.26M | ﹤0.01% |
293,580
+86,800
| +42% | +$414K |
|
|
GWB
2578
DELISTED
Great Western Bancorp, Inc.
GWB
| $1.25M | ﹤0.01% |
31,544
+11,044
| +54% | +$447K |
|
|
SEP
2579
DELISTED
Spectra Engy Parters Lp
SEP
| $1.25M | ﹤0.01% |
31,700
-245,600
| -89% | -$10.3M |
|
2580
Altimmune
ALT
$560M
| $1.25M | ﹤0.01% |
20,954
-471
| -2% | -$30.1K |
|
2581
Acushnet Holdings
GOLF
$5.2B
| $1.25M | ﹤0.01% |
+59,300
| New | +$1.13M |
|
2582
Ohio Valley Banc Corp
OVBC
$211M
| $1.25M | ﹤0.01% |
30,900
-800
| -3% | -$30.3K |
|
2583
Schwab US Aggregate Bond ETF
SCHZ
$10.6B
| $1.24M | ﹤0.01% |
+47,624
| New | +$1.24M |
|
|
FRTX
2584
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
| $1.24M | ﹤0.01% |
2,150
+316
| +17% | +$208K |
|
2585
Global Water Resources
GWRS
$219M
| $1.23M | ﹤0.01% |
132,100
+31,200
| +31% | +$297K |
|
2586
Stock Yards Bancorp
SYBT
$2.64B
| $1.23M | ﹤0.01% |
32,650
-52,300
| -62% | -$2.01M |
|
2587
Comstock Resources
CRK
$3.99B
| $1.23M | ﹤0.01% |
+145,200
| New | +$862K |
|
2588
AZZ Inc
AZZ
$4.55B
| $1.23M | ﹤0.01% |
24,000
-9,000
| -27% | -$426K |
|
2589
Consumer Portfolio Services
CPSS
$205M
| $1.22M | ﹤0.01% |
294,000
-54,500
| -16% | -$239K |
|
|
CDTX
2590
DELISTED
Cidara Therapeutics
CDTX
| $1.22M | ﹤0.01% |
8,965
+1,860
| +26% | +$282K |
|
2591
Norwood Financial Corp
NWFL
$376M
| $1.22M | ﹤0.01% |
36,850
-300
| -0.8% | -$9.12K |
|
2592
WisdomTree International SmallCap Dividend Fund
DLS
$1.08B
| $1.21M | ﹤0.01% |
+15,700
| New | +$1.17M |
|
|
DZSI
2593
DELISTED
DZS Inc. Common Stock
DZSI
| $1.2M | ﹤0.01% |
129,697
+29,800
| +30% | +$231K |
|
|
CMRX
2594
DELISTED
Chimerix, Inc.
CMRX
| $1.2M | ﹤0.01% |
259,152
+65,192
| +34% | +$310K |
|
|
ATRS
2595
DELISTED
Antares Pharma, Inc.
ATRS
| $1.19M | ﹤0.01% |
599,769
-2,184,222
| -78% | -$4.75M |
|
|
CEA
2596
DELISTED
China Eastern Airlines
CEA
| $1.19M | ﹤0.01% |
33,000
-9,200
| -22% | -$259K |
|
|
FNJN
2597
DELISTED
Finjan Holdings, Inc.
FNJN
| $1.19M | ﹤0.01% |
551,600
-172,850
| -24% | -$376K |
|
|
OAKS
2598
DELISTED
Five Oaks Investment Corp.
OAKS
| $1.18M | ﹤0.01% |
294,759
-97,850
| -25% | -$410K |
|
|
SAUC
2599
DELISTED
Diversified Restaurant Holdings, Inc. Common stock
SAUC
| $1.17M | ﹤0.01% |
728,700
-5,200
| -0.7% | -$8.41K |
|
2600
John Wiley & Sons Class A
WLY
$2.63B
| $1.16M | ﹤0.01% |
17,700
-52,917
| -75% | -$3.06M |
|
Similar funds
Jim Simons's Q4 2017 Portfolio in Review
As of Q4 2017, Jim Simons held 3,692 positions worth $90.7B, up 6.7% from $85B the previous quarter. Its ten largest holdings account for 8.4% of the portfolio.
Jim Simons's Q4 2017 filing shows 521 new, 1,724 increased, 1,031 reduced and 386 closed positions. Its largest new stake was Alphabet (Google) Class C: 3,773,700 shares worth $197M. The largest sale was CR Bard Inc., an estimated $455M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 17% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q4 2017 buy was Alphabet (Google) Class C: 3,773,700 shares worth $197M.
- Jim Simons added most to ExxonMobil in Q4 2017, an estimated $521M increase.
- Jim Simons's biggest Q4 2017 reduction was NetEase, cutting an estimated $451M.
- Jim Simons fully exited CR Bard Inc. in Q4 2017, selling an estimated $455M.
- Jim Simons's ten largest holdings make up 8.4% of its $90.7B portfolio in Q4 2017.
- Jim Simons opened 521 new positions and closed 386 in Q4 2017.
- Jim Simons's portfolio value rose 6.7% quarter-over-quarter to $90.7B.
Based on Renaissance Technologies's 13F filing for Q4 2017, filed 13 Feb 2018.